AAVrh10 Mediated Gene Replacement Therapy Targeted to Schwann Cells to Treat CMT1X Demyelinating Neuropathy

被引：0
|
作者：
Kagiava, Alexia [1 ]
Christou, Melina [1 ]
Sargiannidou, Irene [1 ]
Kleopa, Kleopas A. [1 ]
机构：
[1] Cyprus Inst Neurol & Genet, Nicosia, Cyprus
来源：
MOLECULAR THERAPY | 2023年 / 31卷 / 04期
关键词：
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
680
引用
收藏
页码：340 / 340
页数：1
相关论文
共 28 条
  • [1] Gene replacement therapy for CMT1X neuropathy
    Kagiava, Alexia
    Richter, Jan
    Tryfonos, Christina
    Karaiskos, Christos
    Sargiannidou, Irene
    Christodoulou, Christina
    Kleopa, Kleopas
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2018, 23 (04) : 332 - 332
  • [2] AAV9 gene replacement therapy in two mutant mouse models of CMT1X demyelinating neuropathy
    Kagiava, Alexia
    Karaiskos, Christos
    Lapathitis, George
    Sargiannidou, Irene
    Bosch, Assumpcio
    Kleopa, Kleopas
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2021, 26 (03) : 327 - 327
  • [3] AAV9 gene replacement therapy in two mutant mouse models of CMT1X demyelinating neuropathy
    Kagiava, A.
    Karaiskos, C.
    Lapathitis, G.
    Sargiannidou, I.
    Bosch, A.
    Kleopa, K. A.
    HUMAN GENE THERAPY, 2021, 32 (19-20) : A121 - A122
  • [4] Gene replacement therapy in two Golgi-retained CMT1X mutants before and after the onset of demyelinating neuropathy
    Kagiava, Alexia
    Karaiskos, Christos
    Lapathitis, George
    Heslegrave, Amanda
    Sargiannidou, Irene
    Zetterberg, Henrik
    Bosch, Assumpcio
    Kleopa, Kleopas A.
    MOLECULAR THERAPY METHODS & CLINICAL DEVELOPMENT, 2023, 30 : 377 - 393
  • [5] Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1X
    Kagiava, A.
    Richter, J.
    Tryfonos, C.
    Karaiskos, C.
    Heslegrave, A. J.
    Sargiannidou, I
    Rossor, A. M.
    Zetterberg, H.
    Reilly, M. M.
    Christodoulou, C.
    Kleopa, K. A.
    HUMAN MOLECULAR GENETICS, 2019, 28 (21) : 3528 - 3542
  • [6] INTRATHECAL GENE THERAPY IN A NEUROPATHY MODEL EXPRESSING A CMT1X MUTATION
    Kagiava, A.
    Karaiskos, C.
    Richter, J.
    Sargiannidou, I
    Christodoulou, C.
    Kleopa, K. A.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2016, 21 (03) : 268 - 268
  • [7] AAV9-MEDIATED POST-ONSET GENE REPLACEMENT THERAPY BENEFITS TRANSGENIC MODELS OF CMT1X NEUROPATHY
    Kagiava, Alexia
    Karaiskos, Christos
    Lapathitis, George
    Sargiannidou, Irene
    Bosch, Assumpcio
    Kleopa, Kleopas
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2022, 27 : S63 - S63
  • [8] Gene therapy, CMT1X, and the inherited neuropathies
    Shy, Michael E.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2016, 113 (17) : 4552 - 4554
  • [9] Gene therapy after onset of neuropathy provides therapeutic benefit in a model of CMT1X
    Kleopa, Kleopas
    Karaiskos, Christos
    Richter, Jan
    Tryfonos, Christina
    Rossor, Alexander
    Reilly, Mary
    Sargiannidou, Irene
    Christodoulou, Christina
    Kagiava, Alexia
    NEUROLOGY, 2019, 92 (15)
  • [10] AAV9-mediated Schwann cell-targeted gene therapy rescues a model of demyelinating neuropathy
    Kagiava, Alexia
    Karaiskos, Christos
    Richter, Jan
    Tryfonos, Christina
    Jennings, Matthew J.
    Heslegrave, Amanda J.
    Sargiannidou, Irene
    Stavrou, Marina
    Zetterberg, Henrik
    Reilly, Mary M.
    Christodoulou, Christina
    Horvath, Rita
    Kleopa, Kleopas A.
    GENE THERAPY, 2021, 28 (10-11) : 659 - 675
123